Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Retinoblastoma by Phase

  • There are currently 33 ongoing clinical trials involving Retinoblastoma

  • Of the 33 trials,13 trials are in Phase II

  • Furthermore, 7 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Retinoblastoma by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Retinoblastoma, an Oncology condition. The largest number of ongoing clinical trials for Retinoblastoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Retinoblastoma-related drug trials.

Memorial Sloan Kettering Cancer Center, Curie Institute and Sun Yat-sen University: The leading ongoing Retinoblastoma related clinical trial sponsors

Memorial Sloan Kettering Cancer Center, Curie Institute and Sun Yat-sen University are the top sponsors for Retinoblastoma-related ongoing clinical trials.

Seattle Children's Hospital, Y-mAbs Therapeutics Inc, Washington University School of Medicine and The Hospital for Sick Children are among other notable clinical trial sponsors involved in Retinoblastoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Retinoblastoma 

Cyclophosphamide (Sendoxan), Carboplatin (Paraplatin, Carboplat, Paraplatine) and Anecortave acetate are among the key marketed drugs involving Retinoblastoma.

Cyclophosphamide (Sendoxan) is a derivative of nitrogen mustards, acts as an antineoplastic agent. It functions via DNA Synthesis Inhibitor mechanism of action. Cyclophosphamide is formulated as tablets for oral route of administration and as injectable solution for intravenous route of administration. Cyclophosphamide was first approved in 1958 and is marketed globally in the US, Denmark and Mexico by Baxter Healthcare Corp and Hikma Pharmaceuticals Plc.  

Carboplatin (Paraplatin, Carboplat, Paraplatine), is an antineoplastic agent and chemotherapeutic agent. It functions via DNA Synthesis Inhibitor mechanism of action. Carboplatin is formulated as injection for intravenous use. Carboplatin was first approved in 1986 and is marketed globally in the US, Russia, China, Japan, France and Germany by several prominent pharma giants including Corden Pharma Switzerland LLC. 



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward